| P2093 | author name string | Manel Almela | |
| | María Teresa Jiménez de Anta | |
| | Asunción Moreno | |
| | Carlos A Mestres | |
| | José M Gatell | |
| | José M Miró | |
| | Francesc Marco | |
| | Cristina García de la Mària | |
| | Dolors Soy | |
| | Yolanda Armero | |
| | Ana del Río | |
| | Eurídice Amat | |
| | Hospital Clinic Experimental Endocarditis Study Group | |
| P2860 | cites work | Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 |
| | Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis | Q28333659 |
| | Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus | Q28362193 |
| | Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin | Q33750776 |
| | Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus | Q34073176 |
| | Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q34230034 |
| | Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y | Q34426508 |
| | Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 |
| | Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis | Q35280233 |
| | Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination | Q35285000 |
| | Vancomycin pharmacokinetics in normal and morbidly obese subjects | Q35675005 |
| | Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus | Q35879100 |
| | Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy | Q36183890 |
| | Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains | Q36328966 |
| | MRSA--the tip of the iceberg | Q36416464 |
| | Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium | Q36758113 |
| | Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart | Q36991476 |
| | Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia | Q37064359 |
| | Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides | Q39470313 |
| | Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus | Q39746366 |
| | Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. | Q39781254 |
| | Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits | Q39819894 |
| | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 |
| | In vitro bactericidal activity of daptomycin against staphylococci | Q43895572 |
| | Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q44641537 |
| | Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein | Q45023859 |
| | High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 |
| | Staphylococcus aureus endocarditis: a consequence of medical progress | Q46561771 |
| | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 |
| | Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| | methicillin-resistant Staphylococcus aureus | Q595158 |
| P304 | page(s) | 2538-2543 | |
| P577 | publication date | 2008-04-21 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus | |
| P478 | volume | 52 | |